The 'end', and starting from today also the costs, justify the 'means'. When the 'end' refers to the cure of chronic heart failure (CHF) patients, one of the stronger, justified means we dispose of is cardiac resynchronization therapy (CRT). However, the large difference in costs between CRT with (D) or without (P) defibrillator back-up may strongly affect clinical decisions. This is particularly relevant as physicians have to deal with the economic sustainability imposed by their country's health system. The choice between CRT-D and CRT-P in medical refractory patients with ejection fraction <35% and left bundle branch block has always been a cause of anxiety and stress for cardiologists, as these patients meet both indications for CRT and implantable cardiac defibrillator (ICD) implantation. 1 Both European and American guidelines give 'carte blanche' to clinicians, simply specifying that we lack randomized trials supporting the use of CRT-P in patients with New York Heart Association (NYHA) class I and II. On the contrary, in patients with NYHA class III and ambulatory class IV, as well as in frail, older patients with multiple comorbidities, CRT-D is not expected to produce meaningful benefits in survival. 1, 2 However, as we know, clinical evaluation is rather subjective, and physicians often feel restricted in their decisions by medico-legal issues. This leads to a high rate (70-80%) of CRT-D implantations in clinical practice, with high costs and complications (i.e. lead failures, inappropriate shocks). 3 Thus, to face such a considerable decision (end), physicians should be sustained by a useful and objective tool (means), besides clinical evaluation.
During the last years, cardiac magnetic resonance (CMR) has become an important part of the clinical evaluation of cardiovascular patients. Indeed, CMR with late gadolinium enhancement (LGE) has provided invaluable information on both aetiopathogenesis and management of ventricular arrhythmias and sudden cardiac death (SCD), thus paving the way for personalized care. A growing body of literature is supporting the strong prognostic value of CMR scar analysis in predicting arrhythmia-free survival. In fact, not only the presence of scar and its mass, but other features such as heterogeneity of myocardial tissue surrounding the scar (i.e. prevalence of border zone over dense scar) were shown to be powerful predictors of ventricular arrhythmias. 4 In CRT candidates this assumes a particular meaning, especially because the response to biventricular pacing has shown to decrease ventricular arrhythmias while improving ejection fraction (bringing the patient out from the ICD indication window). To solve this issue, Acosta et al. designed the GAUDI-CRT study published in 2018. 5 They performed CMR in 217 patients, 86 ischaemic and 131 non-ischaemic, before they received CRT-D or CRT-P, purely on the basis of clinical evaluation. Interstitial myocardial fibrosis was detected in 125 (57%) patients and analysed in a quantitative (calculation of scar mass and border zone mass) and qualitative manner (identification of border zone channels through dedicated software). During a median follow-up of 35.5 (12-62) months, 25 of 125 patients (20%) experienced life-threatening ventricular arrhythmias and SCD. These patients had greater scar mass, wider scar heterogeneity and more border zone channels. On the contrary, those with a scar mass <10 g plus the absence of border zone channels as well as a scar mass <10 g plus border zone mass <5.3 g had a 100% negative predictive value to undergo the primary endpoint.
Based on these important results, the same group decided to move forward by investigating the economic side of this strategy. In this issue of the journal, Crespo and colleagues present a cost-effectiveness analysis performed on 181 patients of the GAUDI-CRT study. 6 Using a Markov model to simulate the progression of heart failure, they tested during a longer follow-up (four years) the hypothesis that a CMR-based approach for CRT-candidate screening could be more cost-effective than the simple clinical evaluation.
And results proved they were right. By applying a CMR-based approach, 64% of patients not showing high risk criteria (defined as scar mass >10 g, border zone mass >5.3 g, border zone channels 1) had been previously implanted with a CRT-D using only clinical judgement. None of these patients experienced ICD shocks during follow-up, thus they were over-protected. The authors calculated that almost E7487 could have been saved over the lifetime of each overprotected patient not needing ICD. On the other hand, only 8% of patients classified as high-risk with CMR had undergone CRT-P implantation, being theoretically under protected. However, these patients mainly died due to non-SCD or non-cardiac causes.
The effectiveness analysis in terms of both life-years gained and quality adjusted life years gained confirmed the superiority of the CMR-based approach. The overall cost saving in European countries would be of E702 m annually using CMR for screening CRT candidates, being higher for those countries (i.e. Germany, Italy, United Kingdom) where CRT-Ds are the most implanted devices.
Beyond the pioneering translational outlook of the GAUDI-CRT study, the socio-economic impact investigated in the current analysis is timely due to the general lack of resources and funds across the different health care systems worldwide. The sample size analysed was relatively small and data were not randomized. However, an aspect which confers validity to the results is that the endpoint 'ICD-shocks' was only a surrogate one for SCD. This makes the over-protection more plausible for a higher patient rate. Although these findings call for external validation by larger prospective studies, they certainly add an important piece to the complex and 'expensive' mosaic of CHF management.
There remain, however, a few open questions to be answered:
1. Is there any difference between ischaemic and nonischaemic patients in terms of outcome? Could CMR really be useful in all clinical contexts? Based on few studies, the addition of the ICD in 'ischaemic' CRT candidates seems to be associated with a more pronounced reduction of all-cause mortality risk. 7 However, in the GAUDI-CRT study there was no significant association between ischaemic cardiomyopathy and the primary endpoint. Although LGE areas were observed in 90.7% of ischaemic patients versus 35.9% of non-ischaemic patients (p < 0.001), it should be noted that, among patients with scar, no differences were found in scar features between ischaemic and non-ischaemic patients. 5 Furthermore, some overlap cases or concomitant aetiologies can be observed, thus rendering CMR even more useful for diagnosis in all types of cardiomyopathy.
2. Can we draw any conclusion, based on these findings, in patients with heart failure with midrange ejection fraction (HFmrEF)? Although overall risk is higher in patients with left ventricular ejection fraction (LVEF) below 35%, the absolute number of SCDs is greater in patients with HFmrEF. This epidemiological paradox occurs because the latter subgroup is much larger. 8 Myocardial fibrosis assessment by LGE with CMR identifies a group of patients with LVEF 40% at increased risk of SCD. 9 Furthermore, CRT should be implanted to prevent ejection fraction deterioration in selected patients with mild left ventricular systolic dysfunction and pacing indication with anticipated high right ventricle stimulation rate. 10 In this setting CMR could play a key role for selecting patients needing CRT-D instead of CRT-P, but randomized data are warranted. The ongoing CMR GUIDE trial (Cardiovascular Magnetic Resonance Guided Management of Mild-Moderate Left Ventricular Systolic Dysfunction; NCT01918215) is examining the role of ICD in patients with evidence of myocardial fibrosis in the context of mild types of cardiomyopathies.
In conclusion, the study by Crespo et al. answered an unmet clinical need: what is the best approach to be used among CRT candidates? In the era of 'precision medicine' where we dispose of highly sophisticated and costly device therapies (end) to cure our patients, we still use subjective (NYHA class) and poorly precise (ejection fraction) means to select them. Helpful tools (CMR), providing us with a detailed assessment of myocardial fibrosis extension and heterogeneity (in terms of scar mass and border zone mass and channels) are now available and they seem to be much more effective than costly.
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